1
|
Knabe C, Stiller M, Kampschulte M, Wilbig J, Peleska B, Günster J, Gildenhaar R, Berger G, Rack A, Linow U, Heiland M, Rendenbach C, Koerdt S, Steffen C, Houshmand A, Xiang-Tischhauser L, Adel-Khattab D. A tissue engineered 3D printed calcium alkali phosphate bioceramic bone graft enables vascularization and regeneration of critical-size discontinuity bony defects in vivo. Front Bioeng Biotechnol 2023; 11:1221314. [PMID: 37397960 PMCID: PMC10311449 DOI: 10.3389/fbioe.2023.1221314] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 06/05/2023] [Indexed: 07/04/2023] Open
Abstract
Introduction: Recently, efforts towards the development of patient-specific 3D printed scaffolds for bone tissue engineering from bioactive ceramics have continuously intensified. For reconstruction of segmental defects after subtotal mandibulectomy a suitable tissue engineered bioceramic bone graft needs to be endowed with homogenously distributed osteoblasts in order to mimic the advantageous features of vascularized autologous fibula grafts, which represent the standard of care, contain osteogenic cells and are transplanted with the respective blood vessel. Consequently, inducing vascularization early on is pivotal for bone tissue engineering. The current study explored an advanced bone tissue engineering approach combining an advanced 3D printing technique for bioactive resorbable ceramic scaffolds with a perfusion cell culture technique for pre-colonization with mesenchymal stem cells, and with an intrinsic angiogenesis technique for regenerating critical size, segmental discontinuity defects in vivo applying a rat model. To this end, the effect of differing Si-CAOP (silica containing calcium alkali orthophosphate) scaffold microarchitecture arising from 3D powder bed printing (RP) or the Schwarzwalder Somers (SSM) replica fabrication technique on vascularization and bone regeneration was analyzed in vivo. In 80 rats 6-mm segmental discontinuity defects were created in the left femur. Methods: Embryonic mesenchymal stem cells were cultured on RP and SSM scaffolds for 7d under perfusion to create Si-CAOP grafts with terminally differentiated osteoblasts and mineralizing bone matrix. These scaffolds were implanted into the segmental defects in combination with an arteriovenous bundle (AVB). Native scaffolds without cells or AVB served as controls. After 3 and 6 months, femurs were processed for angio-µCT or hard tissue histology, histomorphometric and immunohistochemical analysis of angiogenic and osteogenic marker expression. Results: At 3 and 6 months, defects reconstructed with RP scaffolds, cells and AVB displayed a statistically significant higher bone area fraction, blood vessel volume%, blood vessel surface/volume, blood vessel thickness, density and linear density than defects treated with the other scaffold configurations. Discussion: Taken together, this study demonstrated that the AVB technique is well suited for inducing adequate vascularization of the tissue engineered scaffold graft in segmental defects after 3 and 6 months, and that our tissue engineering approach employing 3D powder bed printed scaffolds facilitated segmental defect repair.
Collapse
Affiliation(s)
- Christine Knabe
- Department of Experimental Orofacial Medicine, Philipps University Marburg, Marburg, Germany
| | - Michael Stiller
- Department of Experimental Orofacial Medicine, Philipps University Marburg, Marburg, Germany
- Department of Prosthodontics, Philipps University Marburg, Marburg, Germany
| | - Marian Kampschulte
- Department of Radiology, Justus Liebig University Giessen, Giessen, Germany
| | - Janka Wilbig
- Department of Biomaterials and Multimodal Processing, Federal Institute for Materials Research and Testing, Berlin, Germany
| | - Barbara Peleska
- Department of Prosthodontics, Philipps University Marburg, Marburg, Germany
| | - Jens Günster
- Department of Biomaterials and Multimodal Processing, Federal Institute for Materials Research and Testing, Berlin, Germany
| | - Renate Gildenhaar
- Department of Biomaterials and Multimodal Processing, Federal Institute for Materials Research and Testing, Berlin, Germany
| | - Georg Berger
- Department of Biomaterials and Multimodal Processing, Federal Institute for Materials Research and Testing, Berlin, Germany
| | - Alexander Rack
- Structure of Materials Group, ESRF (European Synchroton Radiation Facility), Grenoble, France
| | - Ulf Linow
- Department of Biomaterials and Multimodal Processing, Federal Institute for Materials Research and Testing, Berlin, Germany
| | - Max Heiland
- Department of Oral and Maxillofacial Surgery, Charité University Medical Center Berlin (Charité-Universitätsmedizin Berlin), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Carsten Rendenbach
- Department of Oral and Maxillofacial Surgery, Charité University Medical Center Berlin (Charité-Universitätsmedizin Berlin), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Steffen Koerdt
- Department of Oral and Maxillofacial Surgery, Charité University Medical Center Berlin (Charité-Universitätsmedizin Berlin), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Claudius Steffen
- Department of Oral and Maxillofacial Surgery, Charité University Medical Center Berlin (Charité-Universitätsmedizin Berlin), Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
| | - Alireza Houshmand
- Department of Experimental Orofacial Medicine, Philipps University Marburg, Marburg, Germany
| | - Li Xiang-Tischhauser
- Department of Experimental Orofacial Medicine, Philipps University Marburg, Marburg, Germany
| | - Doaa Adel-Khattab
- Department of Experimental Orofacial Medicine, Philipps University Marburg, Marburg, Germany
- Department of Periodontology, Ain Shams University, Cairo, Egypt
| |
Collapse
|
2
|
Qiao Q, Xu L, Li Q, Wang Y, Lu H, Zhao N, Pu Y, Wang L, Guo Y, Guo C. BMPR1α promotes osteolytic lesion of oral squamous cell carcinoma by SHH‐dependent osteoclastogenesis. Cancer Sci 2022; 113:1639-1651. [PMID: 35279920 PMCID: PMC9128187 DOI: 10.1111/cas.15330] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Revised: 02/18/2022] [Accepted: 03/09/2022] [Indexed: 11/28/2022] Open
Abstract
Oral squamous cell carcinoma (OSCC) is an aggressive tumor that usually invades the maxilla or mandible. The extent and pattern of mandibular bone invasion caused by OSCC are the most important factors determining the treatment plan and patients' prognosis. Yet, the process of mandibular invasion is not fully understood. The following study explores the molecular mechanism that regulates the mandibular invasion of OSCC by focusing on bone morphogenetic protein receptor 1α (BMPR1α) and Sonic hedgehog (SHH) signals. We found that BMPR1α was positively correlated to bone defect of OSCC patients. Mechanistically, BMPR1α signaling regulated the differentiation and resorption activity of osteoclasts through the interaction of OSCC cells and osteoclast progenitors, and this process was mediated by SHH secreted by tumor cells. The inhibition of SHH protected bone from tumor‐induced osteolytic activity. These results provide a potential new treatment strategy for controlling OSCC from invading the jawbones.
Collapse
Affiliation(s)
- Qiao Qiao
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
| | - Le Xu
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
- Shandong Provincial Hospital Affiliated to Shandong First Medical University Shandong 250021 PR China
| | - Qingxiang Li
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
| | - Yifei Wang
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
| | - Han Lu
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
- Shanghai Stomotological Hospital Fudan University Shanghai 200001 PR China
| | - Ning Zhao
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
| | - Yinfei Pu
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
- The Second Outpatient Department Peking University School and Hospital of Stomatology, Beijing, 100081, PR China6 Department of Biomedical Engineering, College of Engineering, Peking University Beijing 100871 PR China
| | - Lin Wang
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
| | - Yuxing Guo
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
| | - Chuanbin Guo
- Department of Oral and Maxillofacial Surgery Peking University School and Hospital of Stomatology Beijing 100081 PR China
- National Clinical Research Center for Oral Diseases Beijing 100081 PR China
- National Engineering Laboratory for Digital and Material Technology of Stomatology Beijing 100081 PR China
- Beijing Key Laboratory of Digital Stomatology Peking University School and Hospital of Stomatology Beijing 100081 PR China
| |
Collapse
|
3
|
Chang KW, Hung WW, Chou CH, Tu HF, Chang SR, Liu YC, Liu CJ, Lin SC. LncRNA MIR31HG Drives Oncogenicity by Inhibiting the Limb-Bud and Heart Development Gene ( LBH) during Oral Carcinoma. Int J Mol Sci 2021; 22:ijms22168383. [PMID: 34445087 PMCID: PMC8395036 DOI: 10.3390/ijms22168383] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 07/30/2021] [Accepted: 08/03/2021] [Indexed: 11/17/2022] Open
Abstract
The miR-31 host gene (MIR31HG) encodes a long non-coding RNA (LncRNA) that harbors miR-31 in its intron 2; miR-31 promotes malignant neoplastic progression. Overexpression of MIR31HG and of miR-31 occurs during oral squamous cell carcinoma (OSCC). However, the downstream effectors modulated by MIR31HG during OSCC pathogenesis remain unclear. The present study identifies up-regulation of MIR31HG expression during the potentially premalignant disorder stage of oral carcinogenesis. The potential of MIR31HG to enhance oncogenicity and to activate Wnt and FAK was identified when there was exogenous MIR31HG expression in OSCC cells. Furthermore, OSCC cell subclones with MIR31HG deleted were established using a Crispr/Cas9 strategy. RNA sequencing data obtained from cells expressing MIR31HG, cells with MIR31HG deleted and cells with miR-31 deleted identified 17 candidate genes that seem to be modulated by MIR31HG in OSCC cells. A TCGA database algorithm pinpointed MMP1, BMP2 and Limb-Bud and Heart development (LBH) as effector genes controlled by MIR31HG during OSCC. Exogenous LBH expression decreases tumor cell invasiveness, while knockdown of LBH reverses the oncogenic suppression present in MIR31HG deletion subclones. The study provides novel insights demonstrating the contribution of the MIR31HG-LBH cascade to oral carcinogenesis.
Collapse
Affiliation(s)
- Kuo-Wei Chang
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (K.-W.C.); (H.-F.T.); (C.-J.L.)
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (W.-W.H.); (C.-H.C.); (S.-R.C.); (Y.-C.L.)
- Department of Stomatology, Taipei Veterans General Hospital, Taipei 112, Taiwan
| | - Wan-Wen Hung
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (W.-W.H.); (C.-H.C.); (S.-R.C.); (Y.-C.L.)
| | - Chung-Hsien Chou
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (W.-W.H.); (C.-H.C.); (S.-R.C.); (Y.-C.L.)
| | - Hsi-Feng Tu
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (K.-W.C.); (H.-F.T.); (C.-J.L.)
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (W.-W.H.); (C.-H.C.); (S.-R.C.); (Y.-C.L.)
- Department of Dentistry, National Yang Ming Chiao Tung Hospital, Yilan 260, Taiwan
| | - Shi-Rou Chang
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (W.-W.H.); (C.-H.C.); (S.-R.C.); (Y.-C.L.)
| | - Ying-Chieh Liu
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (W.-W.H.); (C.-H.C.); (S.-R.C.); (Y.-C.L.)
| | - Chung-Ji Liu
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (K.-W.C.); (H.-F.T.); (C.-J.L.)
- Department of Dentistry, Taipei MacKay Memorial Hospital, Taipei 104, Taiwan
| | - Shu-Chun Lin
- Department of Dentistry, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (K.-W.C.); (H.-F.T.); (C.-J.L.)
- Institute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei 112, Taiwan; (W.-W.H.); (C.-H.C.); (S.-R.C.); (Y.-C.L.)
- Department of Stomatology, Taipei Veterans General Hospital, Taipei 112, Taiwan
- Correspondence: ; Fax: +886-2-2826-4053
| |
Collapse
|
4
|
Affolter A, Lammert A, Kern J, Scherl C, Rotter N. Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer. Front Cell Dev Biol 2021; 9:666515. [PMID: 34307351 PMCID: PMC8296983 DOI: 10.3389/fcell.2021.666515] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Accepted: 04/30/2021] [Indexed: 12/12/2022] Open
Abstract
Despite the current progress in the development of new concepts of precision medicine for head and neck squamous cell carcinoma (HNSCC), in particular targeted therapies and immune checkpoint inhibition (CPI), overall survival rates have not improved during the last decades. This is, on the one hand, caused by the fact that a significant number of patients presents with late stage disease at the time of diagnosis, on the other hand HNSCC frequently develop therapeutic resistance. Distinct intratumoral and intertumoral heterogeneity is one of the strongest features in HNSCC and has hindered both the identification of specific biomarkers and the establishment of targeted therapies for this disease so far. To date, there is a paucity of reliable preclinical models, particularly those that can predict responses to immune CPI, as these models require an intact tumor microenvironment (TME). The "ideal" preclinical cancer model is supposed to take both the TME as well as tumor heterogeneity into account. Although HNSCC patients are frequently studied in clinical trials, there is a lack of reliable prognostic biomarkers allowing a better stratification of individuals who might benefit from new concepts of targeted or immunotherapeutic strategies. Emerging evidence indicates that cancer stem cells (CSCs) are highly tumorigenic. Through the process of stemness, epithelial cells acquire an invasive phenotype contributing to metastasis and recurrence. Specific markers for CSC such as CD133 and CD44 expression and ALDH activity help to identify CSC in HNSCC. For the majority of patients, allocation of treatment regimens is simply based on histological diagnosis and on tumor location and disease staging (clinical risk assessments) rather than on specific or individual tumor biology. Hence there is an urgent need for tools to stratify HNSCC patients and pave the way for personalized therapeutic options. This work reviews the current literature on novel approaches in implementing three-dimensional (3D) HNSCC in vitro and in vivo tumor models in the clinical daily routine. Stem-cell based assays will be particularly discussed. Those models are highly anticipated to serve as a preclinical prediction platform for the evaluation of stable biomarkers and for therapeutic efficacy testing.
Collapse
Affiliation(s)
- Annette Affolter
- Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | | | | | | | | |
Collapse
|
5
|
Bridgewater HE, Date KL, O’Neil JD, Hu C, Arrand JR, Dawson CW, Young LS. The Epstein-Barr Virus-Encoded EBNA1 Protein Activates the Bone Morphogenic Protein (BMP) Signalling Pathway to Promote Carcinoma Cell Migration. Pathogens 2020; 9:pathogens9070594. [PMID: 32708289 PMCID: PMC7400503 DOI: 10.3390/pathogens9070594] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2020] [Revised: 07/15/2020] [Accepted: 07/17/2020] [Indexed: 12/18/2022] Open
Abstract
The Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) protein is expressed in all virus-associated malignancies, where it performs an essential role in the maintenance, replication and transcription of the EBV genome. In recent years, it has become apparent that EBNA1 can also influence cellular gene transcription. Here, we demonstrate that EBNA1 is able to stimulate the expression of the Transforming growth factor-beta (TGFβ) superfamily member, bone morphogenic protein 2 (BMP2), with consequential activation of the BMP signalling pathway in carcinoma cell lines. We show that BMP pathway activation is associated with an increase in the migratory capacity of carcinoma cells, an effect that can be ablated by the BMP antagonist, Noggin. Gene expression profiling of authentic EBV-positive nasopharyngeal carcinoma (NPC) tumours revealed the consistent presence of BMP ligands, established BMP pathway effectors and putative target genes, constituting a prominent BMP “signature” in this virus-associated cancer. Our findings show that EBNA1 is the major viral-encoded protein responsible for activating the BMP signalling pathway in carcinoma cells and supports a role for this pathway in promoting cell migration and possibly, metastatic spread.
Collapse
Affiliation(s)
- Hannah E. Bridgewater
- Warwick Medical School, Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK; (H.E.B.); (C.W.D.)
| | - Kathryn L. Date
- Institute for Cancer & Genomic Sciences, College of Medicine & Dentistry, University of Birmingham, Birmingham B15 2TT, UK; (K.L.D.); (J.D.O.); (C.H.); (J.R.A.)
| | - John D. O’Neil
- Institute for Cancer & Genomic Sciences, College of Medicine & Dentistry, University of Birmingham, Birmingham B15 2TT, UK; (K.L.D.); (J.D.O.); (C.H.); (J.R.A.)
| | - Chunfang Hu
- Institute for Cancer & Genomic Sciences, College of Medicine & Dentistry, University of Birmingham, Birmingham B15 2TT, UK; (K.L.D.); (J.D.O.); (C.H.); (J.R.A.)
| | - John R. Arrand
- Institute for Cancer & Genomic Sciences, College of Medicine & Dentistry, University of Birmingham, Birmingham B15 2TT, UK; (K.L.D.); (J.D.O.); (C.H.); (J.R.A.)
| | - Christopher W. Dawson
- Warwick Medical School, Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK; (H.E.B.); (C.W.D.)
| | - Lawrence S. Young
- Warwick Medical School, Gibbet Hill Campus, University of Warwick, Coventry CV4 7AL, UK; (H.E.B.); (C.W.D.)
- Correspondence: ; Tel.: +44-2476-752-38
| |
Collapse
|
6
|
Luo WL, Luo MX, He RZ, Ying LF, Luo J. Multi-Omics Analysis Reveals the Pan-Cancer Landscape of Bone Morphogenetic Proteins. Med Sci Monit 2020; 26:e920943. [PMID: 32248202 PMCID: PMC7156877 DOI: 10.12659/msm.920943] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background Bone morphogenetic proteins (BMPs) are widely involved in cancer development. However, a wealth of conflicting data raises the question of whether BMPs serve as oncogenes or as cancer suppressors. Material/Methods By integrating multi-omics data across cancers, we comprehensively analyzed the genomic and pharmacogenomic landscape of BMP genes across cancers. Results Surprisingly, our data indicate that BMPs are globally downregulated in cancers. Further genetics and epigenetics analyses show that this abnormal expression is driven by copy number variations, especially heterozygous amplification. We next assessed the BMP-associated pathways and demonstrated that they suppress cell cycle and estrogen hormone pathways. Bone morphogenetic protein interacts with 58 compounds, and their dysfunction can induce drug sensitivity. Conclusions Our results define the landscape of the BMP family at a systems level and open potential therapeutic opportunities for cancer patients.
Collapse
Affiliation(s)
- Wen-Li Luo
- Department of Orthopedics, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, China (mainland)
| | - Ming-Xing Luo
- Department of Orthopedics, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, China (mainland)
| | - Rong-Zhen He
- Department of Orthopedics, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, China (mainland)
| | - Lv-Fang Ying
- Department of Orthopedics, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, China (mainland)
| | - Jian Luo
- Department of Orthopedics, Ningbo Hangzhou Bay Hospital, Ningbo, Zhejiang, China (mainland)
| |
Collapse
|
7
|
SOX9 promotes nasopharyngeal carcinoma cell proliferation, migration and invasion through BMP2 and mTOR signaling. Gene 2019; 715:144017. [PMID: 31357026 DOI: 10.1016/j.gene.2019.144017] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2018] [Revised: 07/25/2019] [Accepted: 07/25/2019] [Indexed: 12/13/2022]
Abstract
SRY-related high-mobility-group box 9 (SOX9) is a member of the SOX family of transcription factors. Accumulating evidence has shown that SOX9 plays a significant role in various malignancies. However, the role of SOX9 in nasopharyngeal carcinoma (NPC) remains unknown. In the present study, up-regulation of SOX9 was observed in both NPC tissues and different NPC cells. Overexpression of SOX9 promoted NPC cell proliferation, migration and invasion. Conversely, knock down of SOX9 inhibited NPC proliferation, colony formation, migration and invasion. Mechanistically, SOX9 bound directly to the promoter region of BMP2 and increased BMP2 expression. In addition, overexpression of SOX9 activated the mTOR pathway partly through BMP2. Collectively, these results identify a novel role for SOX9 as a potential therapeutic marker for the prevention and treatment of NPC.
Collapse
|
8
|
Suton P, Bolanca A, Grgurevic L, Erjavec I, Nikles I, Muller D, Manojlovic S, Vukicevic S, Petrovecki M, Dokuzovic S, Luksic I. Prognostic significance of bone morphogenetic protein 6 (BMP6) expression, clinical and pathological factors in clinically node-negative oral squamous cell carcinoma (OSCC). J Craniomaxillofac Surg 2018; 47:80-86. [PMID: 30503606 DOI: 10.1016/j.jcms.2018.10.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 09/14/2018] [Accepted: 10/04/2018] [Indexed: 01/27/2023] Open
Abstract
Bone morphogenetic protein 6 (BMP6) has unique properties regarding structure and function in supporting bone formation during development and adult life. Despite its known role in various malignant tumors, the prognostic significance of BMP6 expression in oral squamous cell carcinoma (OSCC) remains unknown. The aim of the study was to investigate immunohistochemical expression of BMP6 in OSCC in correlation with clinical and pathological parameters, disease recurrence and survival. In addition, we investigated other parameters in order to identify prognosticators of neck metastases and final outcome. The study included 120 patients with clinically T1-3N0 OSCC who were primarily surgically treated between 2003 and 2008. There were 99 (82.5%) male and 21 (17.5%) female patients. The five-year disease-specific survival for the whole cohort was 79.7%. Tumors smaller than 2 cm in diameter showed higher incidence of strong BMP6 expression. No statistical correlation was observed between other clinico-pathological factors and BMP6 expression. Expression of BMP6 was not associated with disease recurrence and survival. BMP6 may not serve as prognosticator of final outcome or recurrence in clinically node-negative OSCC subjects. In multivariate analysis predictors of poorer survival were positive surgical margin, moderate tumor cell differentiation and pathological involvement of levels IV and/or V.
Collapse
Affiliation(s)
- Petar Suton
- Department of Radiotherapy and Medical Oncology, University Hospital for Tumors, University Hospital Centre "Sisters of Mercy", Ilica 197, 10000, Zagreb, Croatia
| | - Ante Bolanca
- Department of Oncology and Nuclear Medicine, University Hospital Centre "Sisters of Mercy", Vinogradska Cesta 29, 10000, Zagreb, Croatia
| | - Lovorka Grgurevic
- University of Zagreb School of Medicine, Laboratory of Mineralized Tissues, Center for Translational and Clinical Research, Salata 3, 10000, Zagreb, Croatia
| | - Igor Erjavec
- University of Zagreb School of Medicine, Laboratory of Mineralized Tissues, Center for Translational and Clinical Research, Salata 3, 10000, Zagreb, Croatia
| | - Iva Nikles
- Department of Radiotherapy and Medical Oncology, University Hospital for Tumors, University Hospital Centre "Sisters of Mercy", Ilica 197, 10000, Zagreb, Croatia
| | - Danko Muller
- University of Zagreb School of Medicine, Department of Pathology, University Hospital Dubrava, Avenue Gojko Susak 6, 10000, Zagreb, Croatia
| | - Spomenka Manojlovic
- University of Zagreb School of Medicine, Department of Pathology, University Hospital Dubrava, Avenue Gojko Susak 6, 10000, Zagreb, Croatia
| | - Slobodan Vukicevic
- University of Zagreb School of Medicine, Laboratory of Mineralized Tissues, Center for Translational and Clinical Research, Salata 3, 10000, Zagreb, Croatia
| | - Mladen Petrovecki
- University of Rijeka School of Medicine, Department of Medical Informatics, Ulica Brace Branchetta 20, 51000, Rijeka, Croatia
| | - Stjepan Dokuzovic
- Department for Traumatology and Orthopaedic Surgery, University Hospital Dubrava, Avenue Gojko Susak 6, 10000, Zagreb, Croatia
| | - Ivica Luksic
- University of Zagreb School of Medicine, Department of Maxillofacial Surgery, University Hospital Dubrava, Avenue Gojko Susak 6, 10000, Zagreb, Croatia.
| |
Collapse
|
9
|
Abstract
Bone morphogenetic proteins (BMPs) are a diverse class of molecules with over 20 growth factor proteins that belong to the transforming growth factor-β (TGF-β) family and are highly associated with bone formation and disease development. Aberrant expression of various BMPs has been reported in several cancer tissues. Biological function studies have elicited the dual role of BMPs in both cancer development and suppression. Furthermore, a variety of BMP antagonists, ligands, and receptors have been shown to reduce or enhance tumorigenesis and metastasis. Knockout mouse models of BMP signaling components have also revealed that the suppression of BMP signaling impairs cancer metastasis. Herein, we highlight the basic clinical background and involvement of BMPs in modulating cancer progression and their dynamic interactions (e.g., with microRNAs) in the tumor microenvironment in addition to their mutations and roles in chemoprevention. We also suggest that BMPs should be considered a powerful putative therapeutic target in tumorigenesis and bone metastasis.
Collapse
Affiliation(s)
- Duc-Hiep Bach
- College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul 151-742, Republic of Korea
| | - Hyen Joo Park
- College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul 151-742, Republic of Korea
| | - Sang Kook Lee
- College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul 151-742, Republic of Korea
| |
Collapse
|
10
|
Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases. Oncotarget 2018; 7:73473-73485. [PMID: 27636990 PMCID: PMC5341992 DOI: 10.18632/oncotarget.11969] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Accepted: 09/02/2016] [Indexed: 01/12/2023] Open
Abstract
The detailed molecular mechanisms and safety issues of recombinant human bone morphogenetic protein-2 (rhBMP-2) usage in bone graft substitution remain poorly understood. To investigate the molecular mechanisms underlying the function of rhBMP-2 in gastric cancer cells, we used microarrays to determine the gene expression patterns related to the effects of rhBMP-2. Based on a gene ontology analysis, several genes were upregulated during the regulation of the cell cycle and BMP signaling pathway. MYC was found to be significantly decreased along with its downstream target genes, the aurora kinases (AURKs), by rhBMP-2 in the network analysis. We further confirmed this finding with western blot data that rhBMP-2 inhibited c-Myc, AURKs, and β-catenin in SNU484 and SNU638 cells. An AURK inhibitor significantly decreased c-Myc expression in gastric cancer cells. Combination treatment with rhBMP-2 and AURK inhibitor resulted in significantly decreased c-Myc expression compared with gastric cancer cells treated with an rhBMP-2 or AURK inhibitor, respectively. Similar effects for decreased c-Myc expression were observed when we silenced β-catenin in gastric cancer cells. These results indicate that rhBMP-2 attenuated the growth of gastric cancer cells via the inactivation of β-catenin via c-Myc and AURKs. Therefore, our findings suggest that rhBMP-2 could be safely used with patients who undergo gastric or gastroesophageal cancer surgery.
Collapse
|
11
|
Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. Biochem Soc Trans 2017; 44:1117-34. [PMID: 27528760 DOI: 10.1042/bst20160069] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Indexed: 12/15/2022]
Abstract
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor-β (TGF-β) family signalling pathway. Similar to TGF-β, the complex roles of BMPs in development and disease are demonstrated by their dichotomous roles in various cancers and cancer stages. Although early studies implicated BMP signalling in tumour suppressive phenotypes, the results of more recent experiments recognize BMPs as potent tumour promoters. Many of these complexities are becoming illuminated by understanding the role of BMPs in their contextual role in unique cell types of cancer and the impact of their surrounding tumour microenvironment. Here we review the emerging roles of BMP signalling in cancer, with a focus on the molecular underpinnings of BMP signalling in individual cancers as a valid therapeutic target for cancer prevention and treatment.
Collapse
|
12
|
Tian H, Zhao J, Brochmann EJ, Wang JC, Murray SS. Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy. Cytokine Growth Factor Rev 2017; 34:73-91. [PMID: 28109670 DOI: 10.1016/j.cytogfr.2017.01.002] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2016] [Revised: 12/14/2016] [Accepted: 01/09/2017] [Indexed: 11/19/2022]
Abstract
Concern regarding safety with respect to the clinical use of human bone morphogenetic protein-2 (BMP-2) has become an increasingly controversial topic. The role of BMP-2 in carcinogenesis is of particular concern. Although there have been many studies of this topic, the results have been contradictory and confusing. We conducted a systematic review of articles that are relevant to the relationship or effect of BMP-2 on all types of tumors and a total of 97 articles were included. Studies reported in these articles were classified into three major types: "expression studies", "in vitro studies", and "in vivo studies". An obvious pattern was that those works that hypothesize an inhibitory effect for BMP-2 most often examined only the proliferative properties of the tumor cells. This subset of studies also contained an extraordinary number of contradictory findings which made drawing a reliable general conclusion impossible. In general, we support a pro-tumorigenesis role for BMP-2 based on the data from these in vitro cell studies and in vivo animal studies, however, more clinical studies should be carried out to help make a firm conclusion.
Collapse
Affiliation(s)
- Haijun Tian
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jie Zhao
- Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Elsa J Brochmann
- Research Service, VA Greater Los Angeles Healthcare System, North Hills, CA, United States; Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, North Hills, CA, United States; Department of Medicine, University of California, Los Angeles, CA, United States
| | - Jeffrey C Wang
- Department of Orthopaedic Surgery, University of Southern California, Los Angeles, CA, United States
| | - Samuel S Murray
- Research Service, VA Greater Los Angeles Healthcare System, North Hills, CA, United States; Geriatric Research, Education and Clinical Center, VA Greater Los Angeles Healthcare System, North Hills, CA, United States; Department of Medicine, University of California, Los Angeles, CA, United States
| |
Collapse
|
13
|
Chiba T, Ishisaki A, Kyakumoto S, Shibata T, Yamada H, Kamo M. Transforming growth factor-β1 suppresses bone morphogenetic protein-2-induced mesenchymal-epithelial transition in HSC-4 human oral squamous cell carcinoma cells via Smad1/5/9 pathway suppression. Oncol Rep 2016; 37:713-720. [PMID: 28035402 PMCID: PMC5355686 DOI: 10.3892/or.2016.5338] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2016] [Accepted: 11/07/2016] [Indexed: 12/23/2022] Open
Abstract
Squamous cell carcinoma is the most common cancer in the oral cavity. We previously demonstrated that transforming growth factor-β1 (TGF-β1) promotes the epithelial-mesenchymal transition (EMT) of human oral squamous cell carcinoma (hOSCC) cells; however, it remains to be clarified whether the TGF-β superfamily member bone morphogenetic protein (BMP) affects this process in hOSCC cells. Here, we examined the independent and collective effects of TGF-β1 and BMP-2 on EMT and mesenchymal‑epithelial transition (MET) in a panel of four hOSCC cell lines. Notably, we found that HSC-4 cells were the most responsive to BMP-2 stimulation, which resulted in the upregulation of Smad1/5/9 target genes such as the MET inducers ID1 and cytokeratin 9 (CK9). Furthermore, BMP-2 downregulated the mesenchymal marker N-cadherin and the EMT inducer Snail, but upregulated epithelial CK9 expression, indicating that BMP-2 prefers to induce MET rather than EMT. Moreover, TGF-β1 dampened BMP-2-induced epithelial gene expression by inhibiting Smad1/5/9 expression and phosphorylation. Functional analysis revealed that TGF-β1 and BMP-2 significantly enhanced HSC-4 cell migration and proliferation, respectively. Collectively, these data suggest that TGF-β positively regulates hOSCC invasion in the primary tumor, whereas BMP-2 facilitates cancer cell colonization at secondary metastatic sites. Thus, the invasive and metastatic characteristics of hOSCC appear to be reciprocally regulated by BMP and TGF-β.
Collapse
Affiliation(s)
- Takahiro Chiba
- Division of Cellular Biosignal Sciences, Department of Biochemistry, Iwate Medical University, Yahaba-cho, Iwate 028-3694, Japan
| | - Akira Ishisaki
- Division of Cellular Biosignal Sciences, Department of Biochemistry, Iwate Medical University, Yahaba-cho, Iwate 028-3694, Japan
| | - Seiko Kyakumoto
- Division of Cellular Biosignal Sciences, Department of Biochemistry, Iwate Medical University, Yahaba-cho, Iwate 028-3694, Japan
| | - Toshiyuki Shibata
- Department of Oral and Maxillofacial Surgery, Gifu University Graduate School of Medicine, Gifu-shi, Gifu 501-1194, Japan
| | - Hiroyuki Yamada
- Division of Oral and Maxillofacial Surgery, Department of Reconstructive Oral and Maxillofacial Surgery, Iwate Medical University School of Dentistry, Morioka, Iwate 020-8505, Japan
| | - Masaharu Kamo
- Division of Cellular Biosignal Sciences, Department of Biochemistry, Iwate Medical University, Yahaba-cho, Iwate 028-3694, Japan
| |
Collapse
|
14
|
Abstract
PURPOSE OF REVIEW A variety of bone grafting materials is available to facilitate the augmentation of defective alveolar ridges. This review evaluates current literature regarding bone grafting materials with emphasis on autologous and allogeneic bone block augmentation. RECENT FINDINGS Autogenous bone is a reliable grafting material providing predictable long-term results with high implant survival/success rates and low morbidity rates. The resorption properties of the iliac crest are well known and are compared with calvarial grafts more prominent. Recent studies demonstrated surgical techniques to prevent graft resorption after iliac crest grafting. Allogeneic block graft and implant survival rates appear promising in short-term clinical studies. SUMMARY At this stage, iliac crest remains the gold standard in large alveolar bone defects. Autogenous material is not a panacea; however, none of the available materials can currently surpass it. Rather, each material has its specific advantage for certain indications. Evident long-term studies of allogeneic bone grafting are lacking. Detected cells in allogeneic bone substitute material are positive for major histocompatibility complex classes I and II. Despite the promising clinical results achieved with allogeneic bone grafts, the current literature lacks sufficient data on antigenicity.
Collapse
|
15
|
Suliman S, Mustafa K, Krueger A, Steinmüller-Nethl D, Finne-Wistrand A, Osdal T, Hamza AO, Sun Y, Parajuli H, Waag T, Nickel J, Johannessen AC, McCormack E, Costea DE. Nanodiamond modified copolymer scaffolds affects tumour progression of early neoplastic oral keratinocytes. Biomaterials 2016; 95:11-21. [PMID: 27108402 DOI: 10.1016/j.biomaterials.2016.04.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2016] [Accepted: 04/03/2016] [Indexed: 11/27/2022]
Abstract
This study aimed to evaluate the tumorigenic potential of functionalising poly(LLA-co-CL) scaffolds. The copolymer scaffolds were functionalised with nanodiamonds (nDP) or with nDP and physisorbed BMP-2 (nDP-PHY) to enhance osteoinductivity. Culturing early neoplastic dysplastic keratinocytes (DOK(Luc)) on nDP modified scaffolds reduced significantly their subsequent sphere formation ability and decreased significantly the cells' proliferation in the supra-basal layers of in vitro 3D oral neoplastic mucosa (3D-OT) when compared to DOK(Luc) previously cultured on nDP-PHY scaffolds. Using an in vivo non-invasive environmentally-induced oral carcinogenesis model, nDP scaffolds were observed to reduce bioluminescence intensity of tumours formed by DOK(Luc) + carcinoma associated fibroblasts (CAF). nDP modification was also found to promote differentiation of DOK(Luc) both in vitro in 3D-OT and in vivo in xenografts formed by DOK(Luc) alone. The nDP-PHY scaffold had the highest number of invasive tumours formed by DOK(Luc) + CAF outside the scaffold area compared to the nDP and control scaffolds. In conclusion, in vitro and in vivo results presented here demonstrate that nDP modified copolymer scaffolds are able to decrease the tumorigenic potential of DOK(Luc), while confirming concerns for the therapeutic use of BMP-2 for reconstruction of bone defects in oral cancer patients due to its tumour promoting capabilities.
Collapse
Affiliation(s)
- Salwa Suliman
- Department of Clinical Dentistry, Center for Clinical Dental Research, University of Bergen, Norway; Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
| | - Kamal Mustafa
- Department of Clinical Dentistry, Center for Clinical Dental Research, University of Bergen, Norway
| | - Anke Krueger
- Institute of Organic Chemistry, University of Würzburg, Würzburg, Germany
| | | | - Anna Finne-Wistrand
- Department of Fibre and Polymer Technology, KTH, Royal Institute of Technology, Stockholm, Sweden
| | - Tereza Osdal
- Department of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway
| | - Amani O Hamza
- Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Yang Sun
- Department of Clinical Dentistry, Center for Clinical Dental Research, University of Bergen, Norway; Department of Fibre and Polymer Technology, KTH, Royal Institute of Technology, Stockholm, Sweden
| | - Himalaya Parajuli
- Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
| | - Thilo Waag
- Institute of Organic Chemistry, University of Würzburg, Würzburg, Germany
| | - Joachim Nickel
- Chair Tissue Engineering and Regenerative Medicine, University Hospital Würzburg, Germany; Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Translational Center 'Regenerative Therapies for Oncology and Musculoskeletal Diseases'- Würzburg Branch, Germany
| | - Anne Christine Johannessen
- Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Emmet McCormack
- Department of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway; Department of Medicine, Haematology Section, Haukeland University Hospital, Bergen, Norway
| | - Daniela Elena Costea
- Gade Laboratory for Pathology, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Center for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
| |
Collapse
|
16
|
Abstract
STUDY DESIGN Literature review. OBJECTIVE To evaluate the association between recombinant human bone morphogenetic protein-2 (rhBMP-2) and malignancy. SUMMARY OF BACKGROUND DATA The use of rhBMP-2 in spine surgery has been the topic of much debate as studies assessing the association between rhBMP-2 and malignancy have come to conflicting conclusions. METHODS A systematic review of the literature was performed using the PubMed-National Library of Medicine/National Institute of Health databases. Only non-clinical studies directly addressing BMP-2 and cancer were included. Articles were categorized by study type (animal, in vitro cell line/human/animal), primary malignancy, cancer attributes, and whether BMP-2 was pro-malignancy or not. RESULTS A total of 4,131 articles were reviewed. Of those, 515 articles made reference to both BMP-2 and cancer, 99 of which were found to directly examine the role of BMP-2 in cancer. Seventy-five studies were in vitro and 24 were animal studies. Forty-three studies concluded that BMP-2 enhanced cancer function, whereas 18 studies found that BMP-2 suppressed malignancy. Thirty-six studies did not examine whether BMP-2 enhanced or suppressed cancer function. Fifteen studies demonstrated BMP-2 dose dependence (9 enhancement, 6 suppression) and one study demonstrated no dose dependence. Nine studies demonstrated BMP-2 time dependence (6 enhancement, 3 suppression). However, no study demonstrated that BMP-2 caused cancer de novo. CONCLUSION Currently, conflicting data exist with regard to the effect of exogenous BMP-2 on cancer. The majority of studies addressed the role of BMP-2 in prostate (17%), breast (17%), and lung (15%) cancers. Most were in vitro studies (75%) and examined cancer invasiveness and metastatic potential (37%). Of 99 studies, there was no demonstration of BMP-2 causing cancer de novo. However, 43% of studies suggested that BMP-2 enhances tumor function, motivating more definitive research on the topic that also includes clinically meaningful dose- and time-dependence. LEVEL OF EVIDENCE 2.
Collapse
|
17
|
Effects of recombinant human bone morphogenetic protein 7 (rhBMP-7) on the behaviour of oral squamous cell carcinoma: a preliminary in vitro study. Br J Oral Maxillofac Surg 2014; 53:158-63. [PMID: 25480012 DOI: 10.1016/j.bjoms.2014.11.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2014] [Accepted: 11/02/2014] [Indexed: 01/18/2023]
Abstract
We investigated the effects of recombinant human bone morphogenetic protein-7 (rhBMP-7) on the behaviour of oral keratinocytes and head and neck squamous cell carcinoma (SCC) cells in vitro. Expression of all three BMP receptors was high (p<0.01), and rhBMP-7 exhibited significant dose-related inhibitory effects on the doubling time and viability of cancer cells (p<0.01), but not on the proliferation or viability of oral keratinocytes. It elicited no significant effect on the invasion of Matrigel in SCC of the head and neck. Results indicate that in cell culture, rhBMP-7 exerts antineoplastic effects. This should be tested in an orthotopic animal model to more closely replicate in vivo effects.
Collapse
|
18
|
Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol 2014; 9:221. [PMID: 25432701 PMCID: PMC4260254 DOI: 10.1186/s13000-014-0221-9] [Citation(s) in RCA: 456] [Impact Index Per Article: 45.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2014] [Accepted: 11/10/2014] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Immunohistochemistry (IHC) is a well-established, widely accepted method in both clinical and experimental parts of medical science. It allows receiving valuable information about any process in any tissue, and especially in bone. Each year the amount of data, received by IHC, grows in geometric progression. But the lack of standardization, especially on the post-analytical stage (interpreting and reporting of results), makes the comparison of the results of different studies impossible. METHODS Comprehensive PubMED literature search with a combination of search words "immunohistochemistry" and "scoring system" was performed and 773 articles describing IHC results were identified. After further manual analysis 120 articles were selected for detailed evaluation of used approaches. RESULTS Six major approaches to the interpretation and presentation of IHC analysis results were identified, analyzed and described. CONCLUSIONS The overview of the existing approaches in evaluation and interpretation of IHC data, which are provided in the article, can be used in bone tissue research and for either better understanding of existing scoring systems or developing a new one. Standard multiparametric, semiquantitative IHC scoring systems should simplify and clarify the process of interpretation and reporting of received data. VIRTUAL SLIDES The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_221.
Collapse
Affiliation(s)
- Nickolay Fedchenko
- Small Animal Clinic, University of Veterinary Medicine, Foundation, Bünteweg 9, 30559, Hannover, Germany.
- Department of Pathological Anatomy and Forensic Medicine, SE "Dnipropetrovsk Medical Academy of Health Ministry of Ukraine", Dzerginskogo st. 9, 49044, Dnipropetrovsk, Ukraine.
| | - Janin Reifenrath
- Small Animal Clinic, University of Veterinary Medicine, Foundation, Bünteweg 9, 30559, Hannover, Germany.
| |
Collapse
|